A Phase I/Ib Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors, including Pancreatic Cancer
The purpose of this phase I trial is to evaluate the safety and tolerability of NGM438 in combination with Pembrolizumab in patients with solid tumors, including pancreatic cancer.
Study ID: 438-IO-101
Trial Phase: Phase I
Trial Sponsor: NGM Biopharmaceuticals, Inc
Therapies Used in This Trial: Pembrolizumab, NGM438